Cancer Forums and News by PhD's


News | Forums Register

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Neck
Pancreatic
Prostate


Cancer Review

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Pancreatic
Prostate


Recent Forum Topics

 
5-FU
TAX 324 Phase III Study Shows Docetaxel Increases Survival in Head, Neck Cancer
By HCat at 2007-02-14 02:20
 


    Marshall R. Posner, MD, medical director of the Head and Neck Oncology Program at the Dana-Farber Cancer Institute in Boston reported at the 2006 annual meeting of the American Society of Clinical Oncology (ASCO) on the randomized Phase III TAX 324 Study Group. 501 patients with locally advanced squamous cell carcinomaterm of the head and neck (SCCHN) (oral cavity, oropharynx, larynx and hypopharynx) were the focus of the study.

 

    In the study, patients receiving docetaxel in combination with cisplatin and 5-FUterm as induction (neoadjuvant) therapy, followed by chemoradiotherapy and surgery were compared to those not receiving docetaxel. The results showed an impressive 70.6 months median overall survival in patients who took docetaxel compared to 30.1 months for those not receiving docetaxel in their treatment. There was a 30% reduction in mortality rate for those patients receiving docetaxel. There was an absolute three-year survival improvement of 14% in the docetaxel group as well. Progression-free survival (PFS) was also significantly greater with the docetaxel regimen with two-year PFS at 53% compared to 42%.

read more | 5485 reads

Reasons Why Cancer Drug Discovery is so Difficult
By HCat at 2007-01-31 23:56
 

    In the perspective article in Nature Reviews Drug Discovery, the authors discuss the challenges facing drug discovery as intricate and numerous. They present a broad picture of drug discovery as three parts pertaining to targets, drugs, and patients. Targets for drug discovery are broken down into two classes, each of which is either essential or non-essential. Essential targets for drug discovery are targets that have essential function within all cells or a specific cell type. That means that the cell has to have this function operating or it will die. Non-essential targets are targets whose function can be lost and the cell will still survive. This concept can also be applied in terms of tissues as a target such as in breast tissue which is considered a non-essential tissue for life. Drugs that inhibit or block essential functions are likely to have narrow therapeutic windows. That is the drugs beneficial dose range is likely to be small before it becomes toxic such as 5-FUterm. 5-FU relies on the principle that cancer cells should be faster growing since they are growing out of control. 5-FU inhibits DNA synthesis, an essential function. Slow growing cells are not as affected as fast growing cells from 5-FU. This therapeutic windowterm is narrow and the consequences or side effectsterm of the narrow window is that 5-FU affects some of the naturally fast growing cells in the body, which is why hair loss is a common side-effect in 5-FU treatment.

read more | 3913 reads

Colorectal Cancer Basics
By HCat at 2007-01-16 12:35

Colorectal Cancer Basics

 

Hereditary CRC

Colorectal cancer (CRC) can be divided into two basic types, hereditary or sporadic.

    Hereditary CRC are germlineterm (passed to offspring) mutations (a damaging change in DNA) with two well described forms. These hereditary mutations are thought to reduce the time it takes for the cells to turn cancerous. Mutations can be thought of in terms of “hits”. One hit is one mutation. It is thought that a normal cell needs 3 to 6 hits to become cancerous. With an inherited mutation, there is one fewer hit needed to reach the correct number to transform the cell to cancer. One odd aspect to CRC is that there is a relatively well defined set of events for the progression from adenomaterm to carcinomaterm.

read more | 29217 reads

ADVENTRX Initiates CoFactor Phase II Clinical Trial in Refractory Breast Cancer
By Dross at 2006-12-30 04:34
 


ADVENTRX Initiates CoFactor Phase II Clinical Trial in Refractory Breast Cancer

 

SAN DIEGO, Dec. 27 -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced the initiation of a Phase II clinical trial using CoFactor(R) in the treatment of refractory metastaticterm breast cancer. CoFactor (ANX-510) is a folate-based biomodulator drug designed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapeutic agent 5-fluorouraciltermtermtermterm (5-FUterm). This study builds on the results of earlier studies and will more fully investigate the efficacy and safety of CoFactor for patients with previously treated, advanced breast cancer. "The initiation of this Phase II clinical trial for CoFactor represents an important milestone in the global registration strategy for our lead product development program," said Evan M. Levine, chief executive officer of ADVENTRX. "We are enthusiastic about CoFactor's potential to enhance the efficacy and safety of 5-FU chemotherapyterm in the treatment of refractory breast cancer."

read more | 1481 reads

Syndicate content
 
Search

sponsored links




Donate


Newsletter



Subscribe to our newsletter to receive info on our site or upcoming clinical trials
Email

Confirm your email address

HTML format
State

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate




Syndicate
Syndicate content


All times are GMT -5. The time now is 04:51 PM.